Table 4 Clinical trials with the combination of lenalidomide and rituximab against FL, DLBCL, and TmL

Fowler et al. [29, 30]

Len: 20 mg, D1-21

N/A

2-yr PFS* 89%

N/A

22 months

Neutropenia (40%)

Rtx: 375 mg/m², D1

Thrombocytopenia (4%)

Dutia et al. [32]

Len: 20 mg, D1-21

N/A

13 months*

N/A

9 months*

Lymphopenia (25%)

Rtx: 375 mg/m², D15 of C1, 1/wk × 4

Neutropenia (19%)

Hyponatremia (19%)

Wang et al. [34] [only FLG3]

Len: 20 mg, D1-21

10.2 months*

2.0 months

25.6 months

24.6 months*

Neutropenia (31% & 22%)

Rtx: 375 mg/m²,

Thrombocytopenia (18% and 16%)

1/wk × 4, only C1

Leonard et al. [33]

Len: 15 mg C1;

N/A

EFS 1.2 years

N/A

1.5 years

Neutropenia (16%)

20 mg C2-12, D1-21

Thrombosis (16%)

Fatigue (9%)

Len: 15 mg C1;

N/A

EFS 2.0 years

N/A

1.5 years

Neutropenia (19%)

20 mg C2-12, D1-21

Fatigue (14%)

Rtx: 375 mg/m^2,, 1/wk × 4

Thrombosis (4%)

Lenalidomide plus rituximab combination as a front-line therapy has not been studied for untreated DLBCL.

Zinzani et al. [41]

Len: 20 mg, D1-21,

N/A

1-yr DFS 34.8%

18-month OS 55%

16 months

Neutropenia (30%)

Rtx: 375 mg/m², D1-21 (during induction)

Thrombocytopenia (14%)

Wang et al. [34]

Len: 20 mg, D1-21

10.2 months*

2.8 months

10.2 months

24.6 months*

Neutropenia (31% & 22%)

Rtx: 375 mg/m²;

Thrombocytopenia (18% and 16%)

1/wk × 4, only C1

Lenalidomide plus rituximab combination as a front-line therapy has not been studied for untreated TmL.

Wang et al. [34]

Len: 20 mg, D1-21

10.2 months*

4.3 months

11.5 months

24.6 months*

Neutropenia (31% & 22%)

Rtx: 375 mg/m².

1/wk × 4, only C1

Thrombocytopenia (18% and 16%)